These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

922 related articles for article (PubMed ID: 32159299)

  • 21. Clinical and Molecular Features in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinosis from Colorectal Cancer.
    Di Giorgio A; Santullo F; Attalla El Halabieh M; Lodoli C; Abatini C; Calegari MA; Martini M; Rotolo S; Pacelli F
    J Gastrointest Surg; 2021 Oct; 25(10):2649-2659. PubMed ID: 34244953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes.
    Rosa F; Galiandro F; Ricci R; Di Miceli D; Quero G; Fiorillo C; Cina C; Alfieri S
    Langenbecks Arch Surg; 2021 Dec; 406(8):2797-2805. PubMed ID: 34661754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of Stable Lung Colorectal Metastases on Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Pantelis A; Ben-Yaacov A; Adileh M; Schtrechman G; Shacham-Shmueli E; Boursi B; Margalit O; Halpern N; Mor E; Assaf D; Maximiliano K; Nissan A; Laks S
    J Gastrointest Surg; 2022 Aug; 26(8):1724-1731. PubMed ID: 35768716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
    Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
    Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peritoneal carcinomatosis in colorectal cancer: Defining predictive factors for successful cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A pilot study.
    Mahmoud AM; Ismail YM; Hussien A; Debaky Y; Ahmed IS; Mikhael HSW; Moneer M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):143-150. PubMed ID: 30472198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
    Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
    Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis.
    Narasimhan V; Tan S; Kong J; Pham T; Michael M; Ramsay R; Warrier S; Heriot A
    Colorectal Dis; 2020 Nov; 22(11):1482-1495. PubMed ID: 32027455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct surgery with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastases.
    Ljunggren M; Nordenvall C; Palmer G
    Eur J Surg Oncol; 2021 Nov; 47(11):2865-2872. PubMed ID: 34116900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center.
    Rosa F; Galiandro F; Ricci R; Di Miceli D; Longo F; Quero G; Tortorelli AP; Alfieri S
    Langenbecks Arch Surg; 2021 Jun; 406(4):1071-1080. PubMed ID: 33611693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perioperative systemic chemotherapy in peritoneal carcinomatosis of lymph node positive colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Kuijpers AM; Mehta AM; Boot H; van Leerdam ME; Hauptmann M; Aalbers AG; Verwaal VJ
    Ann Oncol; 2014 Apr; 25(4):864-869. PubMed ID: 24667719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.
    Canda AE; Arslan C; Terzi C; Sokmen S; Yavuzsen T; Ozkardesler S; Unlu M; Obuz F; Fuzun M
    World J Surg Oncol; 2018 Mar; 16(1):70. PubMed ID: 29587771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Colorectal peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: the experience of a tertiary Asian center.
    Teo MC; Ching Tan GH; Lim C; Chia CS; Tham CK; Soo KC
    Asian J Surg; 2015 Apr; 38(2):65-73. PubMed ID: 25059814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center.
    Rosa F; Galiandro F; Ricci R; Di Miceli D; Longo F; Quero G; Tortorelli AP; Alfieri S
    Langenbecks Arch Surg; 2021 Sep; 406(6):1847-1857. PubMed ID: 33704561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
    Lee L; Alie-Cusson F; Dubé P; Sideris L
    J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus R0 resection for resectable colorectal cancer with peritoneal metastases and low peritoneal cancer index scores: a collaborative observational study from Korea and Japan.
    Kitaguchi D; Park EJ; Baik SH; Sasaki S; Tsukada Y; Ito M
    Int J Surg; 2024 Jan; 110(1):45-52. PubMed ID: 37800569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?
    Chia CS; You B; Decullier E; Vaudoyer D; Lorimier G; Abboud K; Bereder JM; Arvieux C; Boschetti G; Glehen O;
    Ann Surg Oncol; 2016 Jun; 23(6):1971-9. PubMed ID: 26753751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center.
    Huang CQ; Yang XJ; Yu Y; Wu HT; Liu Y; Yonemura Y; Li Y
    PLoS One; 2014; 9(9):e108509. PubMed ID: 25259574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Actual 5-Year Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis of Colorectal Origin.
    Sarfaty E; Khajoueinejad N; Yu AT; Hiotis S; Golas BJ; Sarpel U; Labow DM; Cohen NA
    Ann Surg Oncol; 2024 Mar; 31(3):1970-1979. PubMed ID: 37989953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.